Mineralocorticoid receptor deficiency improves the therapeutic effects of mesenchymal stem cells for myocardial infarction via enhanced cell survival

The poor survival of stem cells seriously limits their therapeutic efficacy for myocardial infarction (MI). Mineralocorticoid receptor (MR) activation plays an important role in the pathogenesis of multiple cardiovascular diseases. Here, we examined whether MR silencing in bone marrow derived mesenchymal stem cells (MSCs) could improve MSCs’ survival and enhance their cardioprotective effects in MI. MSCs from male Sprague‐Dawley rats were transfected with adenoviral small interfering RNA to silence MR (siRNA‐MR). MR silencing decreased hypoxia‐induced MSCs’ apoptosis, as demonstrated by Annexin V/7‐AAD staining. The mechanisms contributing to the beneficial effects of MR depletion were associated with inhibiting intracellular reactive oxygen species production and increased Bcl‐2/Bax ratio. In vivo study, 1 × 106 of MSCs with or without siRNA‐MR were injected into rat hearts immediately after MI. Depletion of MR could improve the MSCs’ survival significantly in infarcted myocardium, associated with more cardiac function improvement and smaller infarct size. Capillary density were also significantly higher in siRNA group with increased expression of vascular endothelial growth factor. Our study demonstrated that silencing MR promoted MSCs’ survival and repair efficacy in ischaemic hearts. MR might be a potential target for enhancing the efficacy of cell therapy in ischaemic heart disease.

[1]  Robert C. Hendel,et al.  Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study) , 2017, Circulation research.

[2]  B. Gersh,et al.  Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART‐1) study , 2017, European journal of heart failure.

[3]  U. Völker,et al.  Pathophysiological aldosterone levels modify the secretory activity of cardiac progenitor cells , 2017, Molecular and Cellular Endocrinology.

[4]  M. Mrkobrada,et al.  Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis , 2016, BMC Cardiovascular Disorders.

[5]  C. Sobey,et al.  Aldosterone-induced oxidative stress and inflammation in the brain are mediated by the endothelial cell mineralocorticoid receptor , 2016, Brain Research.

[6]  Bin Wang,et al.  Mitochondrial reactive oxygen species-mediated NLRP3 inflammasome activation contributes to aldosterone-induced renal tubular cells injury , 2016, Oncotarget.

[7]  U. Völker,et al.  The Other Side of the RAAS: Aldosterone Improves Migration of Cardiac Progenitor Cells , 2015, Journal of cellular physiology.

[8]  Yi Zheng,et al.  A Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in Patients With Ischemic or Nonischemic Heart Failure. , 2015, Circulation research.

[9]  Pu Li,et al.  Exogenous Nkx2.5- or GATA-4-transfected rabbit bone marrow mesenchymal stem cells and myocardial cell co-culture on the treatment of myocardial infarction in rabbits , 2015, Molecular medicine reports.

[10]  V. S. Prakash,et al.  Randomized, double-blind, phase I/II study of intravenous allogeneic mesenchymal stromal cells in acute myocardial infarction. , 2015, Cytotherapy.

[11]  N. Farman,et al.  Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology , 2015, Pharmacological Reviews.

[12]  F. Leenen,et al.  Mineralocorticoid and AT1 receptors in the paraventricular nucleus contribute to sympathetic hyperactivity and cardiac dysfunction in rats post myocardial infarct , 2014, The Journal of physiology.

[13]  A. Androulakis,et al.  Trends in acute myocardial infarction incidence and relative outcomes on a certain insular Mediterranean population. , 2014, International journal of cardiology.

[14]  D. Hausenloy,et al.  The cardioprotective effects of mineralocorticoid receptor antagonists. , 2014, Pharmacology & therapeutics.

[15]  M. Hong,et al.  A Randomized, Open-Label, Multicenter Trial for the Safety and Efficacy of Adult Mesenchymal Stem Cells after Acute Myocardial Infarction , 2013, Journal of Korean medical science.

[16]  J. Funder.  Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine , 2013, Integrated blood pressure control.

[17]  Onju Ham,et al.  Anti-death strategies against oxidative stress in grafted mesenchymal stem cells. , 2013, Histology and histopathology.

[18]  B. Fanburg,et al.  Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension. , 2013, American journal of physiology. Lung cellular and molecular physiology.

[19]  N. Toda,et al.  Aldosterone affects blood flow and vascular tone regulated by endothelium‐derived NO: therapeutic implications , 2013, British journal of pharmacology.

[20]  J. Ge,et al.  High Density Lipoprotein Protects Mesenchymal Stem Cells from Oxidative Stress-Induced Apoptosis via Activation of the PI3K/Akt Pathway and Suppression of Reactive Oxygen Species , 2012, International journal of molecular sciences.

[21]  A. Chouldechova,et al.  Early Stem Cell Engraftment Predicts Late Cardiac Functional Recovery: Preclinical Insights From Molecular Imaging , 2012, Circulation. Cardiovascular imaging.

[22]  A. Mihailidou,et al.  Low-Dose Spironolactone Prevents Apoptosis Repressor With Caspase Recruitment Domain Degradation During Myocardial Infarction , 2012, Hypertension.

[23]  Changting Liu,et al.  Assessment of the green florescence protein labeling method for tracking implanted mesenchymal stem cells , 2012, Cytotechnology.

[24]  K. Fujisaki,et al.  Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  C. Zobel,et al.  Hyperaldosteronism is associated with a decrease in number and altered growth factor expression of endothelial progenitor cells in rats. , 2011, International journal of cardiology.

[26]  P. Galuppo,et al.  Deletion of Cardiomyocyte Mineralocorticoid Receptor Ameliorates Adverse Remodeling After Myocardial Infarction , 2011, Circulation.

[27]  Zhisong He,et al.  Paracrine factors released by GATA-4 overexpressed mesenchymal stem cells increase angiogenesis and cell survival. , 2010, American journal of physiology. Heart and circulatory physiology.

[28]  N. Fukuda,et al.  Effect of eplerenone on endothelial progenitor cells and oxidative stress in ischemic hindlimb. , 2010, American journal of hypertension.

[29]  Alan S. Go,et al.  Population trends in the incidence and outcomes of acute myocardial infarction. , 2010, The New England journal of medicine.

[30]  L. Zentilin,et al.  Cardiomyocyte VEGFR‐1 activation by VEGF‐B induces compensatory hypertrophy and preserves cardiac function after myocardial infarction , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  Joshua M Hare,et al.  A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. , 2009, Journal of the American College of Cardiology.

[32]  R. Kloner,et al.  Promise of blood- and bone marrow-derived stem cell transplantation for functional cardiac repair: putting it in perspective with existing therapy. , 2009, Journal of the American College of Cardiology.

[33]  W. Grossman,et al.  VEGF improves survival of mesenchymal stem cells in infarcted hearts. , 2008, Biochemical and biophysical research communications.

[34]  Samuel Bernard,et al.  Evidence for Cardiomyocyte Renewal in Humans , 2008, Science.

[35]  H. Haider,et al.  Pharmacologically Preconditioned Skeletal Myoblasts Are Resistant to Oxidative Stress and Promote Angiomyogenesis via Release of Paracrine Factors in the Infarcted Heart , 2007, Circulation research.

[36]  Zhongjie Sun,et al.  AAV delivery of mineralocorticoid receptor shRNA prevents progression of cold-induced hypertension and attenuates renal damage , 2006, Gene Therapy.

[37]  Shengshou Hu,et al.  Hypoxia and Serum Deprivation‐Induced Apoptosis in Mesenchymal Stem Cells , 2006, Stem cells.

[38]  Y. Tang,et al.  Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. , 2005, Journal of the American College of Cardiology.

[39]  Y. Geng.  Molecular Mechanisms for Cardiovascular Stem Cell Apoptosis and Growth in the Hearts with Atherosclerotic Coronary Disease and Ischemic Heart Failure , 2003, Annals of the New York Academy of Sciences.

[40]  J. Ingwall,et al.  Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts , 2003, Nature Medicine.

[41]  K Walsh,et al.  Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies. , 2001, Journal of molecular and cellular cardiology.

[42]  W. Rumsey,et al.  Oxygen pressure distribution in the heart in vivo and evaluation of the ischemic "border zone". , 1994, The American journal of physiology.

[43]  Darcy L. DiFede,et al.  Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. , 2014, JAMA.

[44]  B. Gersh,et al.  CD34(+) cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent. , 2011, American heart journal.

[45]  Paul D. Kessler,et al.  Human Mesenchymal Stem Cells Differentiate to a Cardiomyocyte Phenotype in the Adult Murine Heart , 2002, Circulation.